$AIM
AIM ImmunoTech Inc.

2014 Q1 Form 10-K Financial Statement

#000094664414000005 Filed on March 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013 Q3
Revenue $76.00K $36.00K $36.00K
YoY Change 80.95% -32.08% -7.69%
Cost Of Revenue $323.0K $160.0K $252.0K
YoY Change 69.11% -68.63% -74.49%
Gross Profit -$247.0K -$120.0K -$216.0K
YoY Change 65.77% -73.91% -77.24%
Gross Profit Margin -325.0% -333.33% -600.0%
Selling, General & Admin $2.540M $1.760M $2.070M
YoY Change 22.12% -53.56% 24.7%
% of Gross Profit
Research & Development $2.326M $1.530M $2.173M
YoY Change -0.43% -59.2% -7.81%
% of Gross Profit
Depreciation & Amortization $167.0K $230.0K $200.0K
YoY Change -6.7% 27.78% 5.26%
% of Gross Profit
Operating Expenses $2.326M $3.290M $2.173M
YoY Change -0.43% -56.37% -7.81%
Operating Profit -$5.112M -$3.410M -$4.459M
YoY Change 12.06% -57.38% -10.19%
Interest Expense $0.00 $170.0K $90.00K
YoY Change -100.0% -76.71% -74.29%
% of Operating Profit
Other Income/Expense, Net $0.00 $165.0K $85.00K
YoY Change -100.0% -77.05% -75.43%
Pretax Income -$3.840M -$3.200M -$5.140M
YoY Change 6.37% -41.39% -22.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.836M -$3.195M -$5.136M
YoY Change 6.23% -41.47% -22.03%
Net Earnings / Revenue -5047.37% -8875.0% -14266.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$11.64M -$10.00M -$16.06M
COMMON SHARES
Basic Shares Outstanding 179.3M shares 167.7M shares 167.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.55M $18.19M $29.22M
YoY Change -43.05% -58.61% -17.46%
Cash & Equivalents $4.105M $803.0K $1.598M
Short-Term Investments $17.45M $17.39M $27.62M
Other Short-Term Assets $330.0K $360.0K $330.0K
YoY Change 13.79% 12.5% 26.92%
Inventory $0.00 $0.00 $0.00
Prepaid Expenses $333.0K $358.0K $332.0K
Receivables
Other Receivables
Total Short-Term Assets $21.89M $18.55M $29.55M
YoY Change -43.27% -58.52% -18.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.890M $5.053M $5.145M
YoY Change -4.7% -4.52% -53.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $136.0K $136.0K $136.0K
YoY Change 109.23% 109.23% 94.29%
Total Long-Term Assets $13.12M $13.32M $13.33M
YoY Change 0.34% 2.65% 9.85%
TOTAL ASSETS
Total Short-Term Assets $21.89M $18.55M $29.55M
Total Long-Term Assets $13.12M $13.32M $13.33M
Total Assets $35.01M $31.87M $42.88M
YoY Change -32.23% -44.77% -11.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.217M $1.271M $1.723M
YoY Change -26.91% -41.08% -26.37%
Accrued Expenses $1.740M $1.228M $1.822M
YoY Change 37.12% -63.83% 100.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $7.050M
YoY Change -100.0% -100.0% 22.4%
Long-Term Debt Due $30.00K $30.00K $30.00K
YoY Change -25.0% -40.0% -40.0%
Total Short-Term Liabilities $2.988M $2.532M $10.63M
YoY Change -70.2% -79.98% 8.58%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $30.00K
YoY Change -60.0% -66.67% -50.0%
Other Long-Term Liabilities $10.00K $10.00K $70.00K
YoY Change -95.24% -96.67% -96.68%
Total Long-Term Liabilities $30.00K $30.00K $100.0K
YoY Change -88.46% -91.67% -95.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.988M $2.532M $10.63M
Total Long-Term Liabilities $30.00K $30.00K $100.0K
Total Liabilities $3.017M $2.569M $10.73M
YoY Change -70.65% -80.24% -10.38%
SHAREHOLDERS EQUITY
Retained Earnings -$264.2M -$260.3M -$257.1M
YoY Change 6.64% 6.65%
Common Stock $296.2M $289.7M $289.4M
YoY Change 2.47% 0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.99M $29.30M $32.15M
YoY Change
Total Liabilities & Shareholders Equity $35.01M $31.87M $42.88M
YoY Change -32.23% -44.77% -11.74%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$3.836M -$3.195M -$5.136M
YoY Change 6.23% -41.47% -22.03%
Depreciation, Depletion And Amortization $167.0K $230.0K $200.0K
YoY Change -6.7% 27.78% 5.26%
Cash From Operating Activities -$2.895M -$3.180M -$4.020M
YoY Change -50.52% -35.89% 48.89%
INVESTING ACTIVITIES
Capital Expenditures $65.00K -$210.0K -$270.0K
YoY Change -73.36% -79.81% -84.02%
Acquisitions
YoY Change
Other Investing Activities -$40.00K $9.410M $4.590M
YoY Change -100.72% -194.38% -186.6%
Cash From Investing Activities -$177.0K $9.200M $4.320M
YoY Change -103.38% -183.56% -161.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.385M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.374M -6.810M -10.00K
YoY Change -49130.77% -145.37% -100.09%
NET CHANGE
Cash From Operating Activities -$2.895M -3.180M -4.020M
Cash From Investing Activities -$177.0K 9.200M 4.320M
Cash From Financing Activities $6.374M -6.810M -10.00K
Net Change In Cash $3.302M -790.0K 290.0K
YoY Change -629.17% -17.71% -70.71%
FREE CASH FLOW
Cash From Operating Activities -$2.895M -$3.180M -$4.020M
Capital Expenditures $65.00K -$210.0K -$270.0K
Free Cash Flow -$2.960M -$2.970M -$3.750M
YoY Change -51.44% -24.23% 271.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-114000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-43000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
288671000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289563000 USD
CY2013 us-gaap Adjustment For Amortization
AdjustmentForAmortization
196000 USD
CY2012 us-gaap Adjustment For Amortization
AdjustmentForAmortization
40000 USD
CY2011 us-gaap Adjustment For Amortization
AdjustmentForAmortization
165000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1271000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2157000 USD
CY2013Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
0 USD
CY2012Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
0 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1228000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3395000 USD
CY2012Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3395000 USD
CY2013Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1228000 USD
CY2013Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
270000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
466000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4334000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3664000 USD
CY2011 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-2425000 USD
CY2013 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-281000 USD
CY2012 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-85000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271000 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
219000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
262000 USD
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54242702 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
87498004 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34701415 shares
CY2013Q4 us-gaap Assets
Assets
31867000 USD
CY2012Q4 us-gaap Assets
Assets
57699000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
44728000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
18552000 USD
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
27241000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
17391000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
27230000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
17504000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
229000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
12460000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
229000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
12460000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17391000 USD
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
27241000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
11000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
116000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
229000 USD
CY2012Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0 USD
CY2013Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0 USD
CY2013Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
1
CY2013Q4 us-gaap Availableforsale Securities Restricted Current
AvailableforsaleSecuritiesRestrictedCurrent
0 USD
CY2012Q4 us-gaap Availableforsale Securities Restricted Current
AvailableforsaleSecuritiesRestrictedCurrent
14500000 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
33000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
46000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
55000 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
23000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2212000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3103000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2920000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-891000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
183000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1409000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168660370 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166490190 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
168660370 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166490190 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
166000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
168000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16296000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8430000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17008000 USD
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
7046000 USD
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6580000 USD
CY2013 us-gaap Cost Of Revenue
CostOfRevenue
1234000 USD
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
1989000 USD
CY2011 us-gaap Cost Of Revenue
CostOfRevenue
1043000 USD
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
14456000 USD
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
20553000 USD
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
17317000 USD
CY2012Q4 us-gaap Costs And Expenses
CostsAndExpenses
8048000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
5004000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
3682000 USD
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
3819000 USD
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
4604000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
4770000 USD
CY2013Q4 us-gaap Costs And Expenses
CostsAndExpenses
3448000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
4495000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48624000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42641000 USD
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3233000 USD
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2842000 USD
CY2012Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
348000 USD
CY2013Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
40442000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
45578000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
-1503000 USD
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
76000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
128000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
121000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42641000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48624000 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
138000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
148000 USD
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
171000 USD
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2013 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2013 us-gaap Depreciation
Depreciation
671000 USD
CY2011 us-gaap Depreciation
Depreciation
465000 USD
CY2012 us-gaap Depreciation
Depreciation
643000 USD
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
14000 USD
CY2012Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
295000 USD
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
0 USD
CY2012 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
85000 USD
CY2013 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
281000 USD
CY2011 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
2425000 USD
CY2012Q2 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
387000 USD
CY2012Q4 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1817000 USD
CY2012Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
-1968000 USD
CY2012Q1 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
-151000 USD
CY2013Q2 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
102000 USD
CY2013Q4 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
52000 USD
CY2013Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
38000 USD
CY2013Q1 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
89000 USD
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
14000 USD
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
295000 USD
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
2131000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
378000 USD
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
232000 USD
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
177000 USD
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2013 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2011 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2012 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
579000 USD
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
36000 USD
CY2011 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
247000 USD
CY2013 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P17Y
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
20000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
20000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
20000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
20000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
20000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1080000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1034000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6691000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7723000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9056000 USD
CY2012Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
14500000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-617000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
860000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
424000 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1751000 USD
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
201000 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2167000 USD
CY2013 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
71000 USD
CY2012 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
0 USD
CY2011 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
0 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
110000 USD
CY2012 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-200000 USD
CY2012 us-gaap Interest Expense
InterestExpense
24000 USD
CY2011 us-gaap Interest Expense
InterestExpense
41000 USD
CY2013 us-gaap Interest Expense
InterestExpense
16000 USD
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2013 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
143000 USD
CY2011Q3 us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2011-07-26
CY2011Q3 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0250
CY2012 us-gaap Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount
MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount
9000 USD
CY2011 us-gaap Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount
MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount
69000 USD
CY2012 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
24000 USD
CY2013 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
16000 USD
CY2011 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
41000 USD
CY2013 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
143000 USD
CY2011 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
0 USD
CY2012 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
85000 USD
CY2012 us-gaap Inventory Lifo Reserve Effect On Income Net
InventoryLIFOReserveEffectOnIncomeNet
1023000 USD
CY2011 us-gaap Inventory Lifo Reserve Effect On Income Net
InventoryLIFOReserveEffectOnIncomeNet
0 USD
CY2013 us-gaap Inventory Lifo Reserve Effect On Income Net
InventoryLIFOReserveEffectOnIncomeNet
453000 USD
CY2011Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
192000 USD
CY2010Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
249000 USD
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1215000 USD
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
453000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
897000 USD
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
800000 USD
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
9000 USD
CY2013Q2 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32765000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5755000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
898000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1802000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
2569000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
12999000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31867000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57699000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2532000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12649000 USD
CY2013 us-gaap Line Of Credit Facility Asset Restrictions
LineOfCreditFacilityAssetRestrictions
two to one
CY2012Q4 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
85000 USD
CY2013Q4 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2013Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2013Q3 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
800000 USD
CY2013 us-gaap Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount
MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount
800000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
246000 USD
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-800000 USD
CY2011 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
0 USD
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9000 USD
CY2011 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
4000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
136000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
65000 USD
CY2013 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-71000 USD
CY2012 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
-6000 USD
CY2013 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
0 USD
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
211000 USD
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
242000 USD
CY2011 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
234000 USD
CY2011 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-585000 USD
CY2012 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
346000 USD
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8430000 USD
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-16296000 USD
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17008000 USD
CY2012 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax
6000 USD
CY2011 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax
896000 USD
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hemispherx Biopharma, Inc. (&#8220;Company&#8221;) is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company was founded in the early 1970s doing contract research for the National Institutes of Health. Since that time, the Company has established a strong foundation of laboratory, pre-clinical, and clinical data with respect to the development of natural interferon nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's current strategic focus is derived from </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> applications of its </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> core pharmaceutical technology platforms Ampligen&#174; and Alferon N Injection&#174;. The commercial focus for Ampligen&#174; includes application as a treatment for Chronic Fatigue Syndrome ("CFS") and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection&#174; is an FDA approved product with an indication for refractory or recurring genital warts. Alferon&#174; LDO (Low Dose Oral) is a formulation under development targeting influenza. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries. The Company has three domestic subsidiaries BioPro Corp., BioAegean Corp. and Core BioTech Corp., all of which are incorporated in Delaware and are dormant. The Company&#8217;s foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., was established in Belgium in 1998, and has minimal activity. All significant intercompany balances and transactions have been eliminated in consolidatio</font><font style="font-family:inherit;font-size:10pt;">n. </font><font style="font-family:inherit;font-size:10pt;">Certain items in these financial statements have been reclassified to conform to the current period presentation.</font></div></div>
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1624000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28312000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6847000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22268000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16067000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8655000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10096000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16830000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13136000 USD
CY2012 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 USD
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 USD
CY2011 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
62000 USD
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2011 us-gaap Officers Compensation
OfficersCompensation
2299000 USD
CY2013 us-gaap Officers Compensation
OfficersCompensation
2788000 USD
CY2012 us-gaap Officers Compensation
OfficersCompensation
2578000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-14295000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-20340000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-17167000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
691000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
151000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
68000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
161000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
157000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
154000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
183000 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
210000 USD
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
215000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
615000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
529000 USD
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax
0 USD
CY2012 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
1606000 USD
CY2011 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
624000 USD
CY2013 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
791000 USD
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
262000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
346000 USD
CY2012Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
719000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1573000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
176000 USD
CY2013Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
165000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
775000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
349000 USD
CY2011 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10201000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
322000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
358000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23003000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
249000 USD
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
23479000 USD
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20896000 USD
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22658000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
113000 USD
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2012 us-gaap Professional Fees
ProfessionalFees
21000 USD
CY2011 us-gaap Professional Fees
ProfessionalFees
5250 USD
CY2013 us-gaap Professional Fees
ProfessionalFees
21000 USD
CY2011 us-gaap Profit Loss
ProfitLoss
-9015000 USD
CY2012 us-gaap Profit Loss
ProfitLoss
-17354000 USD
CY2013 us-gaap Profit Loss
ProfitLoss
-16225000 USD
CY2012Q1 us-gaap Profit Loss
ProfitLoss
-2308000 USD
CY2012Q4 us-gaap Profit Loss
ProfitLoss
-5459000 USD
CY2012Q3 us-gaap Profit Loss
ProfitLoss
-6587000 USD
CY2012Q2 us-gaap Profit Loss
ProfitLoss
-3000000 USD
CY2013Q4 us-gaap Profit Loss
ProfitLoss
-3195000 USD
CY2013Q2 us-gaap Profit Loss
ProfitLoss
-4283000 USD
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-3611000 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-5136000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9387000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8956000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5292000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5053000 USD
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
150000 USD
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141016935 shares
CY2011 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
71000 USD
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
47000 USD
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
45000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6722000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9508000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8360000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260319000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244094000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29298000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
44700000 USD
CY2011 us-gaap Revenues
Revenues
161000 USD
CY2012 us-gaap Revenues
Revenues
213000 USD
CY2013 us-gaap Revenues
Revenues
150000 USD
CY2012Q1 us-gaap Revenues
Revenues
72000 USD
CY2012Q3 us-gaap Revenues
Revenues
39000 USD
CY2012Q2 us-gaap Revenues
Revenues
49000 USD
CY2012Q4 us-gaap Revenues
Revenues
53000 USD
CY2013Q2 us-gaap Revenues
Revenues
36000 USD
CY2013Q4 us-gaap Revenues
Revenues
36000 USD
CY2013Q3 us-gaap Revenues
Revenues
36000 USD
CY2013Q1 us-gaap Revenues
Revenues
42000 USD
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
213000 USD
CY2011 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
161000 USD
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135432395 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167325584 shares
CY2013Q4 heb Accrued Production Cost
AccruedProductionCost
51000 USD
CY2012Q4 heb Accrued Production Cost
AccruedProductionCost
70000 USD
CY2013 heb Beneficial Owner Percentageof Outstanding Sharesor Voting Power Held
BeneficialOwnerPercentageofOutstandingSharesorVotingPowerHeld
0.2
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Black-Scholes-Merton
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249000 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23003000 USD
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
377000 USD
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
356000 USD
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
376000 USD
CY2012 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
356000 USD
CY2011 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
377000 USD
CY2013 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
376000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37965000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
45947000 USD
CY2011 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-311000 USD
CY2013 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-871000 USD
CY2012 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
331000 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. Accounts requiring the use of significant estimates include valuation allowances for inventory, determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock options calculations, building valuation, fair value of warrants and contingency accruals.</font></div></div>
CY2013 heb Defined Contribution Plan Employer Matching Contribution Minimum Numberof Yearsof Employment
DefinedContributionPlanEmployerMatchingContributionMinimumNumberofYearsofEmployment
P1Y
CY2013 heb Defined Contribution Plan Employer Matching Contribution Vesting Period
DefinedContributionPlanEmployerMatchingContributionVestingPeriod
P1Y
CY2013 heb Employment Agreement Changein Control Percentageof2008 Salary
EmploymentAgreementChangeinControlPercentageof2008Salary
3
CY2013 heb Employment Agreement Maximum Financing Fee Percentageof2008 Salary
EmploymentAgreementMaximumFinancingFeePercentageof2008Salary
2
CY2013 heb Fda Approved Product Period Until Availablefor Commercial Sales
FDAApprovedProductPeriodUntilAvailableforCommercialSales
P18M
CY2013Q1 heb Fair Value Inputs Future Volatility Floorof Historical Stock Values
FairValueInputsFutureVolatilityFloorofHistoricalStockValues
1
CY2013Q1 heb Fair Value Inputs Future Volatility Periodof Historical Stock Values
FairValueInputsFutureVolatilityPeriodofHistoricalStockValues
P100D
CY2013Q1 heb Fair Value Inputs Probabilityof Triggering Put Right
FairValueInputsProbabilityofTriggeringPutRight
0.01
CY2013 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
686000 USD
CY2011 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
2272000 USD
CY2012 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
1328000 USD
CY2012Q3 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2012Q2 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2012Q1 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
1328000 USD
CY2012Q4 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2013Q3 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2013Q4 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2013Q1 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
686000 USD
CY2013Q2 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
CY2013 heb Income Taxes Utilizationof Operating Loss Carryforward Limitation Percentage Changein Ownership
IncomeTaxesUtilizationofOperatingLossCarryforwardLimitationPercentageChangeinOwnership
0.5
CY2013 heb Inventory Production
InventoryProduction
0 USD
CY2012 heb Inventory Production
InventoryProduction
579000 USD
CY2013 heb Inventory Spoilage
InventorySpoilage
453000 USD
CY2012 heb Inventory Spoilage
InventorySpoilage
1023000 USD
CY2011Q4 heb Inventory Valuation Reserves Charged To Expense
InventoryValuationReservesChargedToExpense
192000 USD
CY2012Q4 heb Inventory Valuation Reserves Charged To Expense
InventoryValuationReservesChargedToExpense
1023000 USD
CY2013Q4 heb Inventory Valuation Reserves Charged To Expense
InventoryValuationReservesChargedToExpense
458000 USD
CY2013Q4 heb Inventory Valuation Reserves Write Offs
InventoryValuationReservesWriteOffs
1673000 USD
CY2011Q4 heb Inventory Valuation Reserves Write Offs
InventoryValuationReservesWriteOffs
249000 USD
CY2012Q4 heb Inventory Valuation Reserves Write Offs
InventoryValuationReservesWriteOffs
0 USD
CY2012 heb Issuance Of Common Stock For Accounts Payable And Accrued Expenses
IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses
384000 USD
CY2011 heb Issuance Of Common Stock For Accounts Payable And Accrued Expenses
IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses
71000 USD
CY2013 heb Issuance Of Common Stock For Accounts Payable And Accrued Expenses
IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses
269000 USD
CY2011Q3 heb Margin Account Loan Date Established
MarginAccountLoanDateEstablished
2011-07-26
CY2012Q4 heb Margin Account Loan Liability
MarginAccountLoanLiability
7051000 USD
CY2013Q4 heb Margin Account Loan Liability
MarginAccountLoanLiability
0 USD
CY2013Q4 heb Margin Account Loan Liability
MarginAccountLoanLiability
7051000 USD
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 heb Numberof Applications Core Technological Platforms
NumberofApplicationsCoreTechnologicalPlatforms
4 application
CY2013 heb Numberof Core Pharmaceutical Technology Platforms
NumberofCorePharmaceuticalTechnologyPlatforms
2 platform
CY2013 heb Numberof Officers
NumberofOfficers
5 officer
CY2012 heb Numberof Officers
NumberofOfficers
5 officer
CY2011 heb Numberof Officers
NumberofOfficers
5 officer
CY2012Q4 heb Numberof Officers
NumberofOfficers
3 officer
CY2013 heb Proceeds From Margin Account Loan
ProceedsFromMarginAccountLoan
-7051000 USD
CY2012 heb Proceeds From Margin Account Loan
ProceedsFromMarginAccountLoan
5356000 USD
CY2011 heb Proceeds From Margin Account Loan
ProceedsFromMarginAccountLoan
1695000 USD
CY2011Q3 heb Reduction In Wells Fargo Base Rate Percentage
ReductionInWellsFargoBaseRatePercentage
0.0275
CY2012Q4 heb Related Party Percentageof Common Stock Owned
RelatedPartyPercentageofCommonStockOwned
0.0499
CY2011 heb Settlement Of Accounts Payable And Accrued Expenses Value
SettlementOfAccountsPayableAndAccruedExpensesValue
71000 USD
CY2013 heb Share Based Compensation Plan Percentageof Common Stock Heldof Combined Entity Changein Control Trigger
ShareBasedCompensationPlanPercentageofCommonStockHeldofCombinedEntityChangeinControlTrigger
0.5
CY2012 heb Stock Issued For Settlement Of Accounts Payable
StockIssuedForSettlementOfAccountsPayable
384000 USD
CY2013 heb Stock Issued For Settlement Of Accounts Payable
StockIssuedForSettlementOfAccountsPayable
269000 USD
CY2013Q4 heb Total Fair Value Of Assets And Liabilities On Recurring Basis
TotalFairValueOfAssetsAndLiabilitiesOnRecurringBasis
17377000 USD
CY2012Q4 heb Total Fair Value Of Assets And Liabilities On Recurring Basis
TotalFairValueOfAssetsAndLiabilitiesOnRecurringBasis
41446000 USD
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0000946644
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
179340426 shares
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 dei Entity Public Float
EntityPublicFloat
36034329 USD
CY2013 dei Entity Registrant Name
EntityRegistrantName
HEMISPHERX BIOPHARMA INC

Files In Submission

Name View Source Status
0000946644-14-000005-index-headers.html Edgar Link pending
0000946644-14-000005-index.html Edgar Link pending
0000946644-14-000005.txt Edgar Link pending
0000946644-14-000005-xbrl.zip Edgar Link pending
a1022-armada.htm Edgar Link pending
a1023bioridge.htm Edgar Link pending
exhibit21-2013.htm Edgar Link pending
exhibit231-2013.htm Edgar Link pending
exhibit311-2013.htm Edgar Link pending
exhibit312-2013.htm Edgar Link pending
exhibit321-2013.htm Edgar Link pending
exhibit322-2013.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
heb-20131231.xml Edgar Link completed
heb-20131231.xsd Edgar Link pending
heb-20131231_cal.xml Edgar Link unprocessable
heb-20131231_def.xml Edgar Link unprocessable
heb-20131231_lab.xml Edgar Link unprocessable
heb-20131231_pre.xml Edgar Link unprocessable
heb1231201310k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending